Cancer Cell:阿司匹林或有助抗癌

2012-02-17 MedSci MedSci原创

2月14日,澳大利亚研究人员称,阿司匹林等非甾体抗炎症药物或许能够抑制癌细胞扩散,原因是它们有助于切断输送这类细胞的“高速公路”。 长期以来,研究人员推测,阿司匹林等非甾体抗炎药可帮助抑制恶性肿瘤扩散,却没有能在药理层面解释作用机理。 墨尔本彼得·麦卡勒姆癌症研究中心研究人员14日说,“阿司匹林这类药物的分子……能有效抑制淋巴管扩张,从而削弱肿瘤扩散至身体其他部位的能力”。 在由美国《癌细胞

2月14日,澳大利亚研究人员称,阿司匹林等非甾体抗炎症药物或许能够抑制癌细胞扩散,原因是它们有助于切断输送这类细胞的“高速公路”。

长期以来,研究人员推测,阿司匹林等非甾体抗炎药可帮助抑制恶性肿瘤扩散,却没有能在药理层面解释作用机理。

墨尔本彼得·麦卡勒姆癌症研究中心研究人员14日说,“阿司匹林这类药物的分子……能有效抑制淋巴管扩张,从而削弱肿瘤扩散至身体其他部位的能力”。

在由美国《癌细胞》杂志发表的论文中,研究人员解释,肿瘤细胞扩散时,淋巴管内细胞中一种特定基因改变“表达”,成为肿瘤生长和细胞输送的连接点,可能引发全身淋巴管炎症和扩张。淋巴管一旦扩张,肿瘤细胞经由它扩散的能力随之增强。

阿司匹林可以抑制淋巴管的扩张,达到切断肿瘤细胞输送通道的效果。

研究人员史蒂芬·施特克尔说:“这就好比,我们找到了所有助推(癌细胞扩散)因素之间的关键连接点。”

研究人员预测,这项发现可用来研发新药,遏制乳腺癌、前列腺癌等实体恶性肿瘤的扩散,也可用于在肿瘤细胞扩散前发出“预警”。

doi:10.1016/j.ccr.2011.12.026
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium

Tara Karnezis, Ramin Shayan, Carol Caesar, Sally Roufail, Nicole C. Harris, Kathryn Ardipradja, You Fang Zhang, Steven P. Williams, Rae H. Farnsworth, Ming G. Chai, Thusitha W.T. Rupasinghe, Dedreia L. Tull, Megan E. Baldwin, Erica K. Sloan, Stephen B. Fox, Marc G. Achen, Steven A. Stacker

Lymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are secreted by some primary tumors. We identified regulation of PGDH, the key enzyme in prostaglandin catabolism, in endothelial cells of collecting lymphatics, as a key molecular change during VEGF-D-driven tumor spread. The VEGF-D-dependent regulation of the prostaglandin pathway was supported by the finding that collecting lymphatic vessel dilation and subsequent metastasis were affected by nonsteroidal anti-inflammatory drugs (NSAIDs), known inhibitors of prostaglandin synthesis. Our data suggest a control point for cancer metastasis within the collecting lymphatic endothelium, which links VEGF-D/VEGFR-2/VEGFR-3 and the prostaglandin pathways. Collecting lymphatics therefore play an active and important role in metastasis and may provide a therapeutic target to restrict tumor spread.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958671, encodeId=9df319586e1d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 17 15:24:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780559, encodeId=c0471e8055989, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri May 18 14:24:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868458, encodeId=a77f18684589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 24 22:24:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
    2012-05-17 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958671, encodeId=9df319586e1d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 17 15:24:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780559, encodeId=c0471e8055989, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri May 18 14:24:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868458, encodeId=a77f18684589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 24 22:24:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958671, encodeId=9df319586e1d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 17 15:24:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780559, encodeId=c0471e8055989, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri May 18 14:24:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868458, encodeId=a77f18684589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Sep 24 22:24:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]

相关资讯

糖尿病患者阿司匹林抵抗研究进展

糖尿病患者阿司匹林抵抗研究进展.pdf

AIM:研究表明常服阿司匹林或弊大于利

近日,来自英国研究人员的研究发现,常服阿司匹林可能弊大于利,虽能使心脏病或中风发作几率降低10%,但可能使脑部或胃部出血风险增加三分之一,相关的研究成果“Effect of Aspirin on Vascular and Nonvascular Outcomes,”刊登在最新一期的杂志Archives of Internal Medicine上面。 医学界对阿司匹林是否有助预防心脏病争议不断。研

Diabetes Care:1型糖尿病需大剂量阿司匹林

 瑞典学者的一项研究表明,在1型糖尿病患者中,大剂量阿司匹林才能影响纤维蛋白网络的通透性。论文于2011年12月6日在线发表于《糖尿病护理》(Diabetes Care)杂志。    1型糖尿病患者可形成一种低通透性纤维蛋白网络,后者可能导致心血管疾病(CVD)风险升高。小剂量阿司匹林治疗为CVD的标准疗法,但其在糖尿病患者中的作用较弱。此项研究的主要目标为评估大、小剂量阿司匹林治疗在1型糖尿

2型糖尿病阿司匹林抵抗机制研究进展

  上海交通大学附属第六人民医院李永霞、侍冬成等研究发现,2型糖尿病(DM)患者阿司匹林抵抗(AR)发生率高于非DM患者,与糖基化终末产物(AGEs)及胰岛素抵抗指数(HOMA-IR)升高有关。   为研究2型DM患者服用阿司匹林后AR与AGEs、HOMA-IR的相关性,研究人员入选了2型DM患者合并或未合并冠心病/高血压/脑梗塞后69例及非DM但患有冠心病/高血压/脑梗塞后患者23例,对所有患

阿司匹林中国专家共识(胡大一)

阿司匹林中国专家共识(胡大一)资料下载: 阿司匹林中国专家共识-胡大一.ppt

WARCEF研究:华法林与阿司匹林预防心衰发生卒中、死亡疗效相似

  2012年国际卒中大会上,美国学者报告了一项国际多中心随机、双盲、对照临床试验:WARCEF(华法林/阿司匹林治疗射血分数降低的患者)研究。主要复合终点结果显示,阿司匹林与华法林在患者死亡、缺血性卒中或脑内出血方面疗效相似。   该研究比较了华法林目标[INR(2.75±0.25)]和阿司匹林(ASA,325 mg/d)对窦性心律左室射血分数(LVEF)降低患者的疗效和安全性。